J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1930KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 98(7): 633-638, 1997

Feature topic

CHEMOTHERAPY FOR ADENOCARCINOMA OF THE PANCREAS

1) Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
2) Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

Osamu Ishikawa1), Hiroaki Ohigasi1), Yo Sasaki1), Masao Kameyama1), Toshiyuki Kabuto1), Shoji Nakamori1), Hiroshi Furukawa1), Shingi Imaoka1), Akihiko Nakaizumi2), Hiroyuki Uehara2)

The present article reviews previous reports on the systemic and regional chemotherapies for adenocarcinoma of the pancreas. When non-resectable pancreatic cancer was treated by the systemic chemotherapy, most reports showed that the mean or median survival periods were less than 6 months. Although the respnse rate to multi-drug chemotherapy was superior than that to single-drug chemotherapy, the survival period did not differ significantly between the two. In general, in terms of the patients' survival rates, the combination of chemo-therapy and radiation was slightly superior to either chemotherapy or radiation alone. On the other hand, regional chemotherapy seems to be more promising because our intra-arterial chemotherapy using angiontensin-II has succeeded in improving the mean survival period to 14 months for non-resectable pancreatic cancer. Likewise, liver perfusion chemotherapy via thehepatic artery and portal vein was effective in preventing the development of liver metastasis after pancreatectomy. Considering that the pancreatic cancer is a poorly vascularized tumor, it is essential to deliver a high dose of anti -cancer drug effectively into the cancer tissue. Secondarily, the selection of drug to which the pancreatic cancer cell is sensitive is also important.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.